Yazar "Çeneli, Özcan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Chronic Myeloid Leukemia After Chemoradiotherapy in a Patient with Non-Small Cell Lung Cancer
    (2017) Demircioğlu, Sinan; Korkmaz, Levent; Yılmaz, Seda; Bektaş, Özlen; Çeneli, Özcan; Artaç, Mehmet
    Chronic myeloid leukemia(CML) is a myeloproliferative disease characterized by uncontrolled proliferation of mature and maturing granulocytes. Chronic myeloid leukemia accounts for approximately 15 to 20 percent of leukemias in adults. The incidence is 1-2/10000 per year.1-2 There is only one risk factor, which is ionized radiation.3 There are some publitions in the literature about CML development after chemotherapy and/or radiotherapy. Here we presented a case that CML occured after chemotherapy concurrent with radiotherapy in non-small cell lung cancer patient. Sixty year old man who has diagnosed inoperable lung adenocarcinoma in 2013. Carboplatin concurrent with radiotherapy was administered to him. After 2 years follow-up with no progression of disease, the level of leucocyte was started to increase. White blood cell level was 41700/ul, haemoglobin level was 14.3 g/dl and platelet level was 239000/ul. Peripheral blood smear suggested chronic myeloid leukemia. Bone marrow aspiration and biopsy was performed. The biopsy was supported chronic phase chronic myeloid leukemia. Cytogenetic analysis showed %95 translocation (9;22) in 20 metaphasis. BCR-ABL was detected as 60% IS. Sokal, Hasford and EUTOS risk score was calculated high. Imatinib therapy was started as 400 mg/day. Hematologic response was seen 2 weeks after imatinib treatment. After 3, 6, 12 months, BCR-ABL was detected as 27% IS, 1% IS, and 0.4 IS, respectively. The patient is still being followed as remission for both lung cancer and CML.
  • Küçük Resim
    Öğe
    İbrutinib sonrası gelişen dev ekimoz ve hematom: Olgu sunumu
    (2017) Demircioğlu, Sinan; Çipil, Handan; Çeneli, Özcan; Uğur Bilgin, Aynur
    Kronik lenfositik lösemi ve Mantle hücreli lenfoma da yeni bir tedavi seçeneği olan ibrutinib, yüksek etkinliği ile günümüzde sık kullanılmaya başlanmıştır. Hedefe yönelik monoklonal antikorların yan etkileri sitotoksik tedavilere göre daha hafif seviyede görülmektedir. İbrutinibin de ishal, bitkinlik, ateş, bulantı, kanama, sitopeniler, alerjik reaksiyonlar gibi yan etkileri görülmektedir. Kanama %50 den fazla vakada görülmüştür. Çoğunluğu peteşiyal kanamalar olmasına rağmen hayati tehdit eden kanamalara da yol açmaktadır. Bizde ibrutinibin kanamaya eğilimi olan hastalarda dikkatli kullanılmasını vurgulamak amacıyla, ibrutinib sonrası kanama gelişen vakamızı sunduk.
  • Küçük Resim
    Öğe
    Prostate Involvement in a Patient with Follicular Lymphoma
    (2017) Demircioğlu, Sinan; Çeneli, Özcan; Fındık, Sıdıka; Yılmaz, Seda; Bektaş, Özlen